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1.1 The medical history of bronchiectasis 
Bronchiectasis was first described by Laennec (1) in 1819 as part of a wider work 
describing the use of his novel invention, the stethoscope. A century later, in 1919, 
A. Jex-Blake delivered a lecture at the Hospital for Consumption (London. UK) on the 
conditions which causes bronchiectasis (2). In this pre-antibiotic era a third of patients 
who were identified as having bronchiectasis were secondary to an episode of pneumonia 
or pleurisy, a third due to chronic bronchitis and a further third due to bronchial 
obstruction, the majority of which were malignant tumors. 
 
1.2 Epidemiology 
Recent data on bronchiectasis epidemiology has been collected from cohorts in Finland, 
New Zealand and the USA (3–5). The data from Finland suggested an incidence of 2.7 
per 100,000 people, while in New Zealand an overall incidence in children of 3.7 per 
100,000 was noted but showed wide variations with regards ethnicity. For example, 
children from a Pacific Island descent had an incidence of 17.8 per 100,000 compared 
with an incident of 1.5 per 100,000 for those of a Northern European descent. 
Unsurprisingly, given the often-chronic nature of its development, the prevalence of 
bronchiectasis and hospital admission related to bronchiectasis increased with age. 
Studies from the USA estimate a prevalence of 4.2 per 100,000 people in those aged 18–
34 years, increasing to 271.8 per 100,000 in people aged >75 years (5). 
 
1.3 Etiology 
Non-cystic fibrosis bronchiectasis (NCFBr) is characterized by irreversibly damaged and 
dilated bronchi with impaired muco-ciliary clearance leading to recurrent bacterial 
infection. Inflammation within the bronchial wall can be the result of an infection within 
the airway, inhalation of injurious agents or an endogenous condition such as an 








There are several causes of bronchiectasis: 
 
Table 1- Etiologies of bronchiectasis (9-40). 
 
Structural lung conditions 
Williams-Campbell syndrome 
Mounier Kuhn syndrome 
Ehler Danlos syndrome 
Toxic damage to airways 
Inhalation injury 
Aspiration secondary to neuromascular disease 
GERD 
Obstruction of single bronchus 
Tumor 
Foreign body 
Defects of mucociliary clearance 
Ciliary dyskinesia (primary, secondary) 
Channelopathies (CFTR dysfunction, ENaC dysfunction) 
ABPA (Allergic bronchopulmonary aspergillosis) 
Immunodeficiency 
Common variable immune deficiency (CVID) 
X-linked agammaglobulinaemia (XLA) 
Chronic granulomatous disease (CGD) 
Antibody deficiency with normal Ig 
Secondary immunodeficiency (Hematological malignancy, post 








Bronchiectasis in systemic disease 
Inflammatory bowel disease 
Connective tissue disease 














1.3.1 Abnormal structural lung conditions 
Congenital disorders affecting the structure of the bronchial tree can lead to 
bronchiectasis through a direct effect on the bronchial wall.  
Williams–Campbell syndrome was first described in 1960 after the case reports of five 
children were studied by Williams and Campbell (6). Histological examination of the 
bronchial wall revealed a deficiency or absence of cartilage, mostly from the third 
division of the bronchi down. 
Mounier–Kuhn syndrome (tracheobronchomegaly) is characterized by dilatation of the 
trachea and large bronchi, usually presented in young adults with central lobes 
bronchiectatic disease (Table 2). Its underlying pathology is not clearly understood but 
histological examination has shown atrophy of airway cartilage and smooth muscle.  
 
1.3.2 Obstructive airways disease 
Asthma and COPD conditions would lead to bronchiectasis as both have clearly been 
shown to cause airway inflammation and structural blockage of airways, either through 
bronchospasm or fixed airways obstruction, in the case of COPD. 
 
1.3.2.1 Asthma 
A number of studies have highlighted the presence of airway remodeling in chronic 
asthma patients using high-resolution CT (HRCT) scanning techniques. The airway 
remodelling can vary from mild airway wall thickening to blatant bronchiectasis. 
Bronchial wall thickening has been found in up to 82% of asthmatic patients in a cohort 
(7) and in patients with mild asthma (8). As bronchial wall thickening is indicative of 
airway inflammation this suggests that a significant number of patients with asthma are 
at risk of developing bronchiectasis. 
The prevalence of bronchiectasis in these studies is estimated at 17.5–40% (8). In the 
largest of these studies, which comprised of 463 patients with severe asthma, 40% of 
patients were shown to have evidence of bronchiectasis on HRCT scans (7-8). However, 
study participants were selected for HRCT on the basis of clinical indication, the most 
common being a suspicion of bronchiectasis.  
These studies suggest that bronchiectasis is associated with a more severe obstruction and 
is more apparent in patients who present with a longer history of asthma symptoms, 
consequently a subgroup of severe asthma patients appear to be at risk of developing 





COPD and bronchiectasis share common symptoms of cough with sputum production 
and susceptibility to recurrent exacerbations driven by new or persistent infection. COPD 
is diagnosed on the basis of poorly reversible airflow obstruction and is therefore a 
physiological diagnosis. While bronchiectasis is diagnosed in the presence of airway 
dilatation and airway wall thickening on imaging (usually computed tomography (CT)), 
and is therefore a structural diagnosis. Physiological criteria for the diagnosis of COPD 
and structural criteria for the diagnosis of bronchiectasis create the possibility for 
individual patients to fulfil both, resulting conceptually in either co-diagnosis or an 
overlap syndrome between the two conditions. A study of moderate-to-severe COPD 
patients demonstrated the prevalence of bronchiectasis to be up to 50% (9).  
 
1.3.2.3 α1-antitrypsin deficiency (ATT) 
α1-antitrypsin deficiency is classically associated with predominantly lower lobe 
emphysema. Bronchiectasis has also been associated with the enzyme deficiency, 
whether this is a direct consequence of the deficiency or secondary to the emphysema-
associated airways obstruction is less clear. In a study of patients with severe AAT 
deficiency the vast majority of subjects had some evidence of bronchiectasis on a HRCT 
scan (70 out of 74 subjects), with 27% having clinically significant bronchiectasis with a 
correlation between forced expiratory volume in 1 second (FEV1) and bronchial wall 
thickness (10). 
 
1.3.3 Defects of mucociliary clearance 
Abnormalities of cilia structure and/or motility cause a decreased mucus clearance from 
the lung. These abnormalities can be due to: 
A) Primary ciliary dyskinesia (PCD)- is a genetically heterogenous disorder with 
mutation in genes (DNAI1 and DNAH5) which code for proteins responsible for 
assembly of outer dynein arms. 
As cilia are present throughout the body, patients with PCD will often present with 
multiple symptoms such as sinusitis, recurrent otitis media, infertility and defects of organ 
lateralisation with situs inversus or situs ambiguus. The triad of bronchiectasis, chronic 
sinusitis and situs inversus is also known as Kartagener’s syndrome. 
B) Secondary ciliary dyskinesia- A number of noxious agents, both organic and inorganic, 




bacteria, such as Pseudomonas aeruginosa and Haemophilus influenzae, have been 
shown to disable mucociliary clearance by releasing products that inhibit ciliary beat 
frequency, allowing them to persist and propagate infection (11-12). Inhaled inorganic 
substances such as diesel particles (13) and cigarette smoke (14) have also been shown to 
have a direct effect on ciliary function, inhibiting ciliary beat frequency. It is important 
to note here that no causal role for tobacco smoking and the development of 
bronchiectasis has been made, indeed outside of COPD bronchiectasis appears to be a 
disease of the nonsmoker. 
Aspiration of gastric contents is a well-recognized, but perhaps under diagnosed, cause 
of bronchiectasis. While aspiration of both acid and nonacid stomach contents leads to 




Defects in the ion channels of the epithelial layer can lead to dehydration of the airway 
surfaces, thereby affecting the depth of the periciliary layer and bringing the cilia into 
contact with the viscous mucus layer, further impeding its function. The most widely 
recognized of these defects is that found in CF. Here, the loss of a chloride channel known 
as the CF transmembrane regulator (CFTR) protein leads to the inability of the epithelial 
cells to excrete chloride. 
 
1.3.5 Allergic bronchopulmonary aspergillosis (ABPA)  
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary condition caused by a 
hypersensitivity reaction to the ubiquitous environmental fungus Aspergillus fumigatus. 
It is most commonly seen in patients with pre-existing asthma or CF and is clinically 
characterized by recurrent wheeze, pulmonary infiltrates and the development of 
bronchiectasis. The hypersensitivity reaction has mixed features of immediate 
hypersensitivity (type I), antigen–antibody complexes (type III) and inflammatory cell 
responses (type IV) (15). The inflammatory cell response seen in ABPA shows a 
predominance of T-helper cell type 2 (Th2) cells leading to a release of cytokines 
mediating allergic inflammation (as opposed to the Th1, cytotoxic pathway) (16). The 
type I hypersensitivity reaction causes local degranulation of mast cells and histamine 
release leading to bronchoconstriction. The combination of airway inflammation, which 




bronchospasm leads to a reduction in mucociliary clearance and the development of 
bronchiectasis. As such bronchiectasis in ABPA is common. In three large case studies it 





1.3.6.1 Primary Immunodeficiency 
Defects in the immune system leave the lungs vulnerable to infection and in some cases 
the development of bronchiectasis can be the first indication of immunodeficiency. The 
most common forms of primary immune deficiencies observed in patients with 
bronchiectasis are common variable immune deficiency (CVID), X-linked 
agammaglobulinaemia (XLA) and chronic granulomatous disease (CGD). 
Common variable immune deficiency (CVID)- is characterized by reduced levels of 
immunoglobulins (Igs) with associated recurrent bacterial infections. An increased risk 
of autoimmune conditions and malignancy has also been identified. The majority of 
patients present with recurrent pulmonary infections at a mean age 29 years (20). CVID 
is the most common primary immune deficiency to cause bronchiectasis. A case series 
undertaken in a UK population identified 68% of the patients with CVID as having 
evidence of bronchiectasis (21) 
X-linked agammaglobulinaemia (XLA)- is caused by a mutation of a tyrosine kinase gene 
that is involved in the development of B- lymphocytes, leading to an absence of 
circulating B-lymphocytes and the absence of Igs. Given the severity of the immune 
deficiency it usually presents much earlier than CVID, usually being diagnosed in early 
childhood (22). Despite treatment with replacement Igs, chronic lung disease can still 
develop with the risk of developing bronchiectasis increasing with age (23) 
Chronic granulomatous disease (CGD)- is a group of disorders characterised by a loss of 
phagocytic NADPH oxidase, without which phagocytes are unable to produce the 
reactive oxygen species required to kill ingested bacteria. Infections are mainly due to 
Staphylococcus aureus, Serratia marcescens, Salmonella sp., Klebsiella sp. and 
Burkholderia cepacia. 
Antibody deficiency with normal Igs- In a study of patients with bronchiectasis and 
normal IgG levels, 11% were shown to have specific antibody production deficiencies 




1.3.6.2 Secondary Immunodeficiency 
The development of bronchiectasis in HIV-infected patients has been noted in a number 
of case series. While recurrent pulmonary infection is likely to be the major factor in the 
development of bronchiectasis in these patients, the development of lymphocytic 
interstitial pneumonia may also be implicated (25). 
 
1.3.7 Infections 
A number of childhood respiratory infections have been implicated in the pathogenesis 
of bronchiectasis. The most widely recognized infectious causes of bronchiectasis are 
measles and pertussis infection in the West (26), with tuberculosis being a major cause 
elsewhere. Globally, Mycobacterium tuberculosis infection remains a major cause of 
morbidity and mortality and a significant cause of bronchiectasis. In developed countries 
with screening programs and adequate access to treatment, the incidence of new 
infections remains low. However, the incidence of nontuberculous mycobacterial (NTM) 
pulmonary infections is increasing. These mycobacteria vary in pathogenecity with 
Mycobacterium avium complex (MAC) being the most pathogenic whilst other 
organisms, such as Mycobacterium gordonae and Mycobacterium abscessus, act as 
opportunistic pathogens and are only found in patients with underlying lung diseases. 
The second of these clinical forms is also known as ‘‘Lady Windermere syndrome’’, and 
was first described in 1992 in a case series of 29 predominately elderly, female patients 
(27). The patients had MAC infection with bronchiectasis predominantly affecting the 
middle lobe and lingula. The authors postulated that persistent voluntary cough 
suppression could lead to chronic inflammatory processes in these poorly draining lung 
regions which are susceptible to MAC infection (27). 
 
1.3.8 Bronchiectasis in systemic diseases 
 
1.3.8.1 Inflammatory bowel disease 
 The development of bronchiectasis in patients with ulcerative colitis is well recognized 
phenomenon and the subject of a number of case series (28). Classically, bronchiectasis 
develops after resection of the large bowel, suggesting a common immune system 
response that becomes concentrated on the bronchial wall after the bowel is removed. The 
common embryonic origin and similar structures of bowel and bronchial wall (columnar 




disease and bronchiectasis is less clear with only a small number of case reports detailing 
their coexistence (29), perhaps too few to determine a definite association. 
 
1.3.8.2 Connective tissue disease  
A number of connective tissue diseases have been noted to be associated with 
bronchiectasis, largely based on case series reviews of small numbers of patients. The 
clearest association is that between rheumatoid arthritis and bronchiectasis (30). 
Associations between bronchiectasis and Sjogren’s syndrome (31), systemic sclerosis 
(32), systemic lupus erythematosus (33), ankylosing spondylitis (34-35) and relapsing 
polychondritis (36) have all been made in small case series reviews. 
 
1.3.8.3 Yellow nail syndrome (YNS) 
YNS is a rare syndrome that was first described in 1964 by Samman and White (37) and 
is characterized by bronchiectasis, lymphoedema and a characteristic appearance of the 
nails. The underlying pathological defect is not clear, although a recent study revealing 
an association with chronic rhinosinusitis suggests a possible defect in an inflammatory 
pathway or mucociliary clearance rather than a structural defect within the lung itself 
(38). 
 
1.3.9 Idiopathic bronchiectasis 
In two large studies (39-40), which identified the cause of bronchiectasis in adults, a 
significant proportion of patients (26% and 53%, respectively) were found to have no 
identifiable cause and were labeled as having idiopathic bronchiectasis, the majority of 
whom were found to be female and nonsmokers. As all the patients studied had undergone 
rigorous clinical testing and their history had been reported, leading to the exclusion of 
all known causes, including genetic disorders, it is unlikely under recognition of known 
causes of bronchiectasis could have occurred. 
Finally, another etiology of bronchiectasis is traction bronchiectasis. It is distortion of the 
airways secondary to mechanical traction on the bronchi from fibrosis of the surrounding 
lung parenchyma. Although the airways may become dilated in this situation, the other 
manifestations of bronchiectasis are lacking such inflammation-infection cycle. Traction 
bronchiectasis tends to have an upper lobe distribution in cases of radiation fibrosis and 
sarcoidosis, while the lower lobe is predominantly involved in cases of interstitial lung 





Table 2- Bronchiectasis lobar distribution and associated diseases (17,22,27).  
Location Disease 
Focal  
 Congenital bronchial atresia 
 Foreign body 
 Broncholithiasis 
 Endobronchial neoplasm 
Diffuse  
Upper lung  
 Cystic fibrosis 
 Sarcoidosis 
 Progressive massive fibrosis of pneumoconiosis 
 Radiation fibrosis 
Central lung  
 Allergic bronchopulmonary aspergillosis 
 End stage hypersensitivity pneumonitis 
 Mounier Kuhn (also lower lobe if repeated infections) 
Lower lung  
 Usual interstitial pneumonia (IPF) 
 Nonspecific interstitial pneumonitis 
 Hypogammaglobulinemia 
 Lung and bone transplantation 
 Chronic aspiration 
 Idiopathic 
Right middle lobe 
and lingula 
 
 Atypical mycobacterial infection 
 Immotile cilia syndrome  
 
 
1.4 Diagnostic evaluation 
 
1.4.1 Clinical features 
The classic clinical manifestations of bronchiectasis are cough and the daily production 
of mucopurulent and tenacious sputum lasting months to years. The older literature also 
described "dry bronchiectasis" with episodic hemoptysis and no sputum production, but 
this presentation is less common (41). 
Other, less specific complaints include dyspnea, wheezing, and pleuritic chest pain. 
Patients often report frequent bouts of "bronchitis" requiring therapy with repeated 




infections over several years, although a single episode of severe bacterial pneumonia, 
pertussis, tuberculosis, and Mycoplasma infection can also result in bronchiectasis.  
In a retrospective chart review of 103 patients with bronchiectasis who presented to a 
referral center, the following clinical findings were documented (41): 
1) Symptoms – cough (98% of patients), daily sputum production (78%), dyspnea 
(62 %), rhinosinusitis (73 %), hemoptysis (27 %), and recurrent pleurisy (20 %). 
2) Physical findings – crackles (75 %) and wheezing (22%) were common, with 
digital clubbing occurring in only 2 % of patients. 
 
1.4.2 Laboratory tests 
 
The following studies are typically part of the initial evaluation of a patient with 
bronchiectasis (42): 
 
1.4.2.1 Routine tests performed 
1) Serum immunoglobulins (IgG, IgA, IgM) and serum electrophoresis. 
2) Specific antibody responses to tetanus and Streptococcus pneumoniae and 
Haemophilus influenzae type b capsular polysaccharides. 
3) IgE and IgG to Aspergillus fumigatus +/- RAST testing. 
4) Sputum for routine culture and for Acid fast bacilli 
5) Autoantibodies (according to local policies but may include rheumatoid factor or anti-
cyclic citrullinated protein antibody, Anti-nuclear antibody and testing for Sjogrens 
syndrome). 
 
1.4.2.2 Tests performed in specific circumstances 
1) Genotyping and sweat testing for cystic fibrosis: 
 a) Age <40 years or 
b) Any age with persistent colonization by Staphylococcus aureus or   
Pseudomonas aeruginosa or 
c) Evidence of mal-absorption, male infertility or 
d) Upper lobe disease. 
2) Ciliary investigations (otitis media, chronic upper respiratory tract symptoms since 





a) Localized disease, bronchoscopy may be indicated to exclude proximal 
obstruction.  
b) For patients in whom serial testing of sputum does not yield microbiological 
information and who are not responding well to treatment, bronchoscopic 
sampling of lower respiratory tract secretion may be indicated. 
c) Bronchoscopy is indicated if high resolution CT (HRCT) suggests atypical 
mycobacterial infection and sputum culture is negative. 
d) Cytological examination of bronchoscopic specimens can provide evidence 
supporting gastric aspiration. 
4) Referral to clinical immunology specialist- clinical suspicion of immunodeficiency 




1.4.3.1 Plain radiograph 
Chest x-rays are usually abnormal, but are inadequate in the diagnosis or quantification 
of bronchiectasis. Tram-track opacities are seen in cylindrical bronchiectasis, and air-
fluid levels may be seen in cystic bronchiectasis (Figure 1). Overall there appears to be 
an increase in bronchovascular markings, and bronchi seen end on may appear as ring 
shadows (43). Pulmonary vasculature appears ill-defined, thought to represent 





Figure 1- Chest radiography showing cystic bronchiectasis with multiple cystic airspaces 
(45). 
 
1.4.3.2 CT scan 
The CT signs of bronchiectasis were first described by Naidichet et al. in 1982 (46). 
Although initial studies using 8–10-mm slice thickness showed low sensitivity (47-49), 
the advent of HRCT led to markedly improved sensitivity, resulting in HRCT replacing 
bronchography as the diagnostic reference standard. 
Optimal HRCT technique is important for maximizing diagnostic accuracy. Importantly, 
thin slices of 1–2 mm and a high-resolution lung reconstruction algorithm are used to 
optimize spatial resolution. 
A number of features are helpful in diagnosing bronchiectasis (Figure 2) (43-44): 
1) Bronchus visualized within 1cm of pleural surface 
A) Especially true of lung adjacent to costal pleura 
B) Most helpful sign for early cylindrical change 
2) lack of tapering 
3) Increased broncho-arterial ratio (BAR): 
A) Diameter of a bronchus should measure approximately 0.65-1.0 times that of 
the adjacent pulmonary artery branch 
B) Between 1 and 1.5 may be seen in normal individuals, especially those living 
at high altitude 
C) Greater than 1.5 indicates bronchiectasis 
4) A number of ancillary findings are also recognized: 
A) Bronchial wall thickening: normally wall of bronchus should be less than half 
the width of the accompanying pulmonary artery branch 
B) Mucoid impaction 






Figure 2 - High-resolution computed tomography image showing cystic bronchiectasis 
in the right lung (45). 
 
1.5 Microbiology of non-CF bronchiectasis 
Patients with bronchiectasis are commonly colonized with potentially pathogenic 
microorganisms in the airways (50). These microorganisms can cause lung infections and 
may produce a number of inflammatory mediators that can lead to progressive tissue 
damage and bronchial obstruction. The phenomenon of chronic infection, bronchial 
inflammation and progressive lung injury is called cole's ‘‘vicious cycle’’ hypothesis 
(Figure 3) and is also the reason why prompt evaluation of infection is important (51). 
 
 

















The most commonly cultured pathogens associated with the sputum of NCFBr are 
Haemophilus influenzae and Pseudomonas aeruginosa, with many isolated strains 
showing significant antibiotic resistance (53-55). Characterizations of the most common 
bacteria in bronchiectasis are: 
 
1.5.1 Haemophilus influenzae 
H. influenzae has been reported in 14–52% of patients with non-CF bronchiectasis. It is 
a Gram-negative coccobacillus with specific growth requirements, which can be difficult 
to isolate in the laboratory if mixed with other flora. Some H. influenzae possess a 
polysaccharide capsule and can be typed using type-specific anti-capsule antisera. Those 
with the type B capsule (Hib) can cause invasive infection with bacteraemia, and are most 
familiar as a cause of meningitis or epiglottitis. The use of Hib vaccine has greatly 
reduced the incidence of these life-threatening conditions. H. influenzae with capsule 
types other than type B are relatively rare and are far less pathogenic. The non-
encapsulated strains, referred to as non-typeable H. influenzae (NTHi), are also less 
pathogenic than Hib and only rarely cause bacteraemia. They live as commensals in the 
human upper respiratory tract but can cause otitis media, sinusitis and conjunctivitis, often 
following a primary viral infection. NTHi are a common cause of lower respiratory 
infection in patients with underlying respiratory abnormalities including non-CF 
bronchiectasis (53). The Hib vaccine does not prevent infection with NTHi as it only 
contains the H. influenzae type B capsule antigen. 
NTHi could be an oral contaminant in expectorated sputum; however, studies using a 
protected specimen brush (PSB) at bronchoscopy found NTHi in significant numbers in 
non-CF bronchiectasis, confirming its presence in the lower respiratory tract (54). In 
contrast Haemophilus parainfluenzae, a common commensal organism found in the 
upper respiratory tract, may be cultured from sputum but was not found in PSB samples. 
In patients with COPD the presence of NTHi in sputum was associated with raised 
inflammatory cytokines, whereas patients with H. parainfluenzae in sputum had similar 
levels of cytokines to those who had no microorganisms cultured from their sputum, 
suggesting that even if present in the lower tract it does not have a direct pathogenic role 
(56-57). 
There is little published data on the epidemiology of H. influenzae in non-CF 
bronchiectasis. It may be cultured repeatedly from the same patient over several years, 




repeated episodes of infection. In COPD exacerbation NTHi were found in higher 
numbers and with the appearance of a new strain (58-59). However, other prospective 
study in COPD using molecular typing of H. influenzae and direct analysis of amplified 
DNA from sputum showed persistence of the same strain over prolong periods (60). 
NTHi have various properties that can help explain their pathogenicity and ability to 
persist in the lung. They can adhere to mucus and to various cell types in the human 
respiratory tract using pili and other adhesion molecules. Virulence factors include the 
endotoxin lipo-oligosaccharides (LOS) and immunoglobulin (Ig) – A protease (61). 
NTHi may be able to evade the immune response by varying its surface antigens. 
Mechanisms: include phase variation of LOS (62), and changes to outer membrane 
proteins (63). 
The prevalence of antibiotic resistant NTHi increases over time in patients with non-CF 
bronchiectasis (53). Many are resistant to amidopenicillins (e.g. amoxicillin, ampicillin) 
either due to production of b-lactamase or alteration of penicillin binding proteins. 
Quinolone resistance is now recognized and resistance rates to trimethoprim and 




1.5.2 Pseudomonas aeruginosa 
P. aeruginosa is a versatile non-fermentative Gram-negative bacillus that is found in a 
range of environments. P. aeruginosa is one of the most common isolates found in 12–
43% of non-CF bronchiectasis patients (64). Stable patients with P. aeruginosa have 
poorer lung function and more sputum production when compared with patients with 
other potentially pathogenic microorganisms (64). It has been associated with a poorer 
quality of life and more frequent hospital admissions (65). There is debate over whether 
infection with P. aeruginosa leads to a faster decline in lung function as is seen in CF, or 
whether it is a marker of more damaged lungs (66-67). 
P. aeruginosa possesses a range of virulence factors, although their expression may differ 
between isolates that cause acute infection and those responsible for chronic infection. 
Flagella, type IV pili lipopolysaccharide and exopolysaccharides contribute to the 
adherence to cells and surfaces. Type I and type II secretion systems export protein toxins, 
such as alkaline protease, elastase, exotoxin A and phospholipase C, while type III 




virulence factors include rhamnolipids, pyocyanin and hydrogen cyanide (68). Another 
pathogenicity factor is the ability to form alginate-enhanced biofilms (69) which 
contributes to the persistence of the organism rather than acute tissue damage and, 
together with other adaptations, promotes chronic infection. 
P. aeruginosa can develop resistance by either: 
 1) Producing enzymes that destroy the antibiotic such as AmpC b-lactamase, 
carbapenemases or aminoglycoside modifying enzymes. 
2) Modifying the antibiotic target, such as gyrA for quinolone resistance. 
3) Reducing exposure either by a decrease in permeability or increased removal of the 
antibiotic from the bacterial cell (efflux). Efflux mechanisms often affect more than one 
class of antibiotics and therefore contribute to multi-drug resistance (70). 
 
1.5.3 Streptococcus pneumoniae 
S. pneumoniae is a Gram-positive coccus appearing in pairs and in short chains. It may 
be a harmless commensal in the oro-pharynx but can cause severe and invasive disease. 
It can cause otitis media, sinusitis, lower airway infections in patients with damaged lungs 
such as non-CF bronchiectasis or COPD, but it is rare in CF. Although  
S. pneumoniae can be found in up to 37% of patients with non-CF bronchiectasis, very 
little has been published on its role in this condition. 
S. pneumoniae has a polysaccharide capsule that helps evade opsonisation, and isolates 
lacking the capsule are avirulent. There are over 90 capsule types and the capsule type 
may be one of several factors that determine the pathogenicity of an individual strain (71). 
A polyvalent vaccine containing the most common serotypes is available and 
recommended for use in patients with chronic lung disease 
S. pneumoniae can use a wide variety of molecules to adhere to host cells and produces 
an IgA protease and a toxin, pneumolysin that can promote invasion, inflammation and 
tissue damage (72). Pneumolysin is proinflammatory and has many actions including 
cytolysis, inhibition of cilial beating, and direct activation of the classical complement 
cascade. 
The prevalence of antibiotic resistant S. pneumoniae has increased and in some countries 
very high rates of resistance to penicillin, macrolides and tetracyclines limit the treatment 
options. Penicillin resistance is due to modifications to penicillin binding proteins not by 
the production of a b-lactamase and, therefore, amoxicillin–clavulanate is ineffective. 




S. aureus is a Gram-positive coccus found in clusters that may be part of the normal flora 
in the anterior nares, throat and on moist skin sites such as groin and axilla. Infection is 
by abscess formation, particularly in skin and soft tissues. It is a rare cause of 
characterized respiratory tract infection, but can cause severe pneumonia after influenza. 
It is a common cause of early infection in CF but is less common in non-CF bronchiectasis 
where its presence may indicate undiagnosed CF (40). There is also an association of S. 
aureus with ABPA in non-CF bronchiectasis (73). 
 
1.5.5 Non-tuberculous mycobacteria (NTM) 
Patients with bronchiectasis, as with other chronic lung diseases, are predisposed to 
infection with NTM. Few studies have undertaken a detailed analysis of NTM in the 
context of bronchiectasis. The prevalence of NTM in bronchiectasis may be higher than 
anticipated because of the non-specific symptoms and because routine screening is not 
usually undertaken. In one study, three cases of NTM were detected over 6 years in 91 
patients with bronchiectasis (74). In another, NTM were found in 6% of bronchiectatic 
patients (55). No mycobacteria were isolated in a study of 150 patients over 3 years (40), 
but in this study sputum was sent only if no response to standard treatment occurred.  
Patients with Mycobacterium avium complex infection may develop bronchiectasis over 
years. Middle-aged or elderly women seem particularly prone to this disease (27). 
However, isolation of an opportunist mycobacterial species should not necessarily be 
interpreted as pathogenic. A ‘one-off’ isolate may have been inhaled shortly before the 
sample was provided. Persistent isolation (colonization) may occur without any change 
in clinical status. HRCT scan features can be helpful in confirming infection.  
Once an opportunist organism has been isolated, prolonged follow-up may be required to 
decide whether this represents colonization or infection. Careful follow-up is mandatory 
because colonization can change to infection (42). This will include: 
1) Clinical features - deterioration favoring infection. 
2)  Sputum examination- (repeated culture, smear positive, heavy growth. 
3) Lung function- rapid decline. 
4) HRCT- exudative ‘tree-in-bud’ bronchiolitis, mucus plugging, cavitating nodules, 
rapid progression of disease. 
5) Treatment failure. 
6) The species isolated will also influence the likelihood of infection: M. avium 




However, there is a lack of available data on the frequency of other important pathogens 
such as non- tuberculous mycobacterium (NTM), as well as the role of patient age and 




1.6.1 Aim of the treatment 
The aims of bronchiectasis management are (42): 
1) Reducing symptoms reduce exacerbation frequency. 
2) Preserving lung function.  
3) Improving health related quality of life. 
 Patient education is of great importance as many patients have a high treatment burden 
with physiotherapy regimes, inhaled and oral therapy regimes and frequent hospital visits. 
Optimizing treatment compliance, rapid recognition of exacerbations and appropriate use 
of complex therapies requires active patient engagement. Patients should be advised to 
stop smoking as smoking will accelerate lung function decline and predispose to mortality 
(77). As with most other chronic illnesses, patients with bronchiectasis will be offered the 
annual influenza vaccination in accordance with national guidelines (42). 
 
1.6.2 Airway clearance 
Despite limited evidence, airway clearance techniques are widely considered a key 
component of management (42). There is little high-quality data comparing different 
techniques for effectiveness. The choice is therefore largely determined by patient choice 
and ease of use.  
Chest physiotherapy- chest clearance techniques include physiotherapy regimes such as 
Active Cycle of Breathing Technique and Postural Drainage with or without adjuncts 
such as positive airway pressure devices, (e.g “Flutter” devices providing oscillatory 
positive pressure), or high frequency chest wall oscillation (78). Small, but significant 
improvements can be seen in exercise capacity, sputum volume and HRQOL (Health-
Related Quality of Life) in patients who use chest physiotherapy compared with control 
(79-80). The availability of a physiotherapist or other health professional experience in 
teaching chest clearance techniques is invaluable for patient education. 
Inhaled hyperosmolar agents- As an adjunct to standard chest physiotherapy, nebulized 




saline can improve FEV1 when used in combination with chest physiotherapy (82). 
Recent trials of inhaled mannitol, another hyperosmolar agent, suggest it can increase 
sputum volume compared to placebo, although the overall significance of this to patients 
is not entirely clear (83-84). 
DNase- The experience of recombinant DNase acts as a cautionary tale in extrapolating 
results in cystic fibrosis to patients with non-CF bronchiectasis. Despite being effective 
in selected patients with CF, DNase was shown to be potentially harmful in a randomised 
controlled trial in NCFBE, reducing FEV1 (85). It is therefore not advised for use in this 
group of patients, and highlights the different pathophysiology in NCFB, compared with 
CF associated bronchiectasis. 
 
 Long Term Antibiotics1.6.3  
Long-term suppressive antibiotic therapy aims to reduce the bacterial load in the airways, 
interrupting the ‘vicious cycle’. According to the hypothesis, this should slow down 
disease progression and lead to improved symptoms and a reduction in exacerbation 
frequency (51). 
Until recently there has been a lack of evidence to guide long term antibiotic therapy in 
NCFBr, but the recent publication of a number of randomized controlled trials have 
established clearly that long term antibiotic therapy can reduce exacerbations as well as 
providing other benefits. 
 
 
1.6.3.1 Oral macrolide therapy 
The BAT, BLESS and EMBRACE trails compare the effects of long term macrolide 
therapy (either 6 or 12 months) to placebo (86-88). All these trials have shown a 
significant reduction in exacerbation frequency compared to placebo during the treatment 
period. The BAT trail showed a median exacerbation frequency of 2 in the placebo group 
compared with 0 in the treatment group after 12 months (P<0.001)(87). Both 12-month 
trails showed a reduction in FEV1 decline for the treatment group, although these were 
small and of doubtful clinical significance (87-88). The main concern of macrolide 
therapy is a marked increase in macrolide resistance in oropharyngeal and other bacteria. 
The BAT trial showed macrolide resistance of 88% in the treatment group compared to 
26% on placebo (87). Azithromycin was associated with increased gastrointestinal side 




have been other concerns regarding macrolides including an increased incidence of 
cardiovascular events although no cardiovascular complications were observed in these 
small RCT’s (89-90). 
Macrolides have anti-inflammatory effects including inhibition of inflammatory cell 
migration, cytokine secretion and attenuation of the production of reactive oxygen species 
(91). Whether the benefit of macrolides is attributable to their antibiotic or anti-
inflammatory effect is unclear. 
BTS guidelines recommend consideration of long-term oral antibiotics for patients with 
≥ 3 exacerbations a year or those chronically colonized with Pseudomonas aeruginosa 
(42). These guidelines were written before the publication of the three recent trials and 
given that the EMBRACE trial showed benefit in patients with one or more exacerbations 
per year these recommendations may change. In clinical practice, macrolides are most 
frequently used in patients with three or more exacerbations per year, patients with 
Pseudomonas aeruginosa and also in patients with less frequent exacerbations who 
continue to have significant impairment of quality of life despite standard treatment. 
 
1.6.3.2 Inhaled antibiotic therapy- Nebulized or inhaled antibiotics deliver a high 
concentration of the drug to the airways, reducing systemic absorption and therefore 
theoretically are associated with fewer side effects compared with oral therapy. A 12 
months randomized control trial comparing nebulized gentamicin to nebulized 0.9% 
saline found a significant reduction in bacterial load, associated with decreases in 
exacerbation frequency and improvements in quality of life (92). This was associated with 
a reduction in airway and systemic inflammation (93). A 3-monthes follow-up review 
after treatment was stopped showed all outcome measures returned to baseline suggesting 
that this type of therapy needs to be continued long term for sustained benefit (92). 
Pseudomonas aeruginosa colonization is associated with a worse prognosis in most 
studies (65). Inhaled antibiotics can suppress P.aeruginosa bacterial load and even 
achieved eradication of P.aeruginosa in 30% of patients treated in the nebulized 
gentamicin trial (92,94). Inhaled tobramycin has been successful in treating CF patients 
with chronic Pseudomonas aeruginosa infection (95). A study by Barker et al showed 
nebulized tobramycin also has benefits in non-CF bronchiectasis (95).  During the study, 
tobramycin was given twice daily for 4 weeks. At 6 weeks the pathogen was eradicated 
in 35% of patients while all patients in the placebo group had persistent colonization. 




tobramycin are needed in non-CF bronchiectasis. Several newer agents are now in late 
phase clinical trials including dry power inhaled ciprofloxacin, nebulized liposomal 
ciprofloxacin and inhaled colistin which was the subject of a recent phase III trial 
demonstrating improved quality of life and a reduction in exacerbations in compliant 
patients. 
 
1.6.3.3 Anti-inflammatory therapy 
Bronchiectasis is thought to be predominantly a neutrophil driven disorder, and 
neutrophils are largely resistant to the anti-inflammatory effects of corticosteroids. There 
is no role for oral corticosteroids in bronchiectasis out-with the treatment of ABPA (96). 
Inhaled corticosteroids are currently indicated in patients with asthma, COPD or airway 
hyper-reactivity. They may have some benefits in bronchiectasis. Some studies have 
shown that regular high dose inhaled steroids reduce 24-hour sputum volume, reduce 
inflammatory markers in sputum and improve quality of life (97). However, they have 
not shown any significant improvement in lung function, or exacerbation frequency. A 
Cochrane review acknowledges they have short-term benefits but concludes there is 
insufficient evidence to recommend their routine use (97). Recent data in COPD shows 
an increase in pneumonia with the use of inhaled steroids (98). Whether this is true in 
bronchiectasis is uncertain but would be a concern in a population already at high risk of 
serious respiratory infections. 
A large number of promising anti-inflammatory therapies specifically targeting 
neutrophils, such as neutrophil elastase inhibitors and CXCR2 antagonists are now 















1.6.3.4 Pseudomonas aeruginosa eradication treatment 
In keeping with recommendations in cystic fibrosis, most specialist centers will attempt 
eradication of P. aeruginosa upon first isolation. An attempt should be made to eradicate 
using 14 courses of oral ciprofloxacin. Failure to eradicate P. aeruginosa with oral 
treatment may lead to consideration of intravenous and/or nebulized eradication (Figure 
4). 
 
Figure 4 - The British Thoracic Society guidelines provides a useful algorithm for 
Pseudomonas aeruginosa eradication (42). 
 
1.6.3.5 Treatment of Exacerbations 
An exacerbation is defined as (Figure 5): 
1) Worsening local symptoms – cough, increases sputum volume, change in 
viscosity, increased sputum purulence. 
2) Dyspnea, increase wheeze, hemoptysis. 







Figure 5 - Definition of an exacerbation needing antibiotic therapy (42). 
 
 A sputum sample should be obtained at the initial presentation of an exacerbation and 
sent for culture. While pending sputum culture results, patients should receive treatment 
targeted towards organisms in previous sputum samples, based on previous sensitivity 
results. This emphasizes the importance of sending regular sputum samples while patients 
are clinically stable. Due to the higher bacterial loads and difficulty in achieving antibiotic 
penetration into biofilms, longer courses of therapy are given in bronchiectasis and most 
advocate 14 days for exacerbations. (42). If there is no previous bacteriology, first line 
treatment is amoxicillin 500mg three time a day or clarithromycin 500mg twice a day for 
14 days (Table 3). By consideration of empiric therapy in patient with no previous 
bacteriology, the guideline does not take in consideration certain risk factors: patient age, 










Table 3- Common organisms associated with acute exacerbation of bronchiectasis and 




BTS guidelines state that intravenous antibiotics may be considered in patients who fail 
to respond to oral therapy, or sputum culture reveals organisms to which no oral therapy 
is beneficial (e.g multidrug resistant pseudomonas aeruginosa) or where patients are 
systemically unwell (42). BTS guideline also suggests criteria for inpatient treatment 
which are: 
1) Unable to cope at home. 
2) Development of cyanosis or confusion. 
3) Breathlessness with respiratory rate >25. 
4) Circulatory failure. 
5) Respiratory failure. 
6) Temperature >38oC. 
7) Intravenous therapy required in patients with clinical failure after oral antibiotics 
 







Figure 6 - Definition of successful treatment of an exacerbation. 
 P, purulent; MP, mucopurulent; M, mucoid. 
 
1.6.4 Pulmonary rehabilitation 
Patients with bronchiectasis with significant breathlessness benefit from pulmonary 
rehabilitation and should be routinely referred for this service (100). 
 
1.7 Parapneumonic effusion 
 
1.7.1 Parapneumonic effusion as an alarming sign in pneumonia 
Despite the advent of potent antibiotics, bacterial pneumonia still results in significant 
morbidity and mortality in the American population. The annual incidence of bacterial 
pneumonia is estimated to be 4 million, with approximately 25% of patients requiring 
hospitalization (101). Because as many as 40% of hospitalized patients with bacterial 
pneumonia have an accompanying pleural effusion (102), effusions associated with 
pneumonia, parapneumonic effusions, account for a large percentage of pleural effusions.  
The morbidity and mortality rates in patients with pneumonia and pleural effusions are 




hospitalized with community acquired pneumonia, patients with pleural effusions were 
2.7 times more likely to be treatment failure than were those without pleural effusions 
(103). In another study, the relative risk of mortality in patients with community acquired 
pneumonia was 7 times higher for patients with bilateral pleural effusions and 3.4 times 
higher for patients with unilateral pleural effusions of moderate or greater size as 
compared with other patients with community acquired pneumonia alone (104). In 
assessing risks of patients with community acquired pneumonia, the presence of a pleural 
effusion is given the same weight as a Po2 less than 60mmHg (105). Espana et al (106) 
recommended that any patient with pneumonia and a loculated effusion or an effusion 
greater than 2 cm in thickness on the decubitus be hospitalized. Some of the increased 
morbidity and mortality in the patients with parapneumonic effusion are due to 
mismanagement of the pleural effusion (107). 
 
1.7.2 Definition of parapneumonic effusion  
A parapneumonic effusion is a pleural effusion associated with lung infection (108). 
Early in the course of parapneumonic effusion, the pleura become inflamed with leakage 
of cellular elements, protein and fluid into the pleural space, forming the effusion. 
Subsequent bacterial invasion results in a frank empyema, the presence of which often 
requires thoracentesis. A delay in the diagnosis and initiation of proper therapy for 
infectious effusions leads to increases in the complication rate. These delays are more 
common in patients with coexisting heart failure or malignancy (109-110). 
Parapneumonic pleural effusions are divided into three groups or stages based upon 
pathogenesis. 
 
1. Uncomplicated parapneumonic effusion — An uncomplicated parapneumonic 
effusion forms when lung interstitial fluid increases during pneumonia and moves across 
the adjacent visceral pleural membrane. The pleural fluid is characterized by "exudative" 
chemistries and an influx of neutrophils into the pleural space. An effusion forms when 
the resorptive capacity of the pleural space is exceeded; it resolves with resolution of the 
pneumonia. 
2. Complicated parapneumonic effusion — A complicated parapneumonic effusion 
develops when there is bacterial invasion of the pleural space. Bacterial invasion typically 
leads to an increased number of neutrophils and the development of pleural fluid acidosis, 




addition, lysis of neutrophils increases the lactate dehydrogenase concentration in the 
pleural fluid to values often in excess of 1000 IU/L. Perhaps, because the bacterial count 
is low or because anaerobic cultures are not done, cultures of fluid from complicated 
parapneumonic effusions are sometimes falsely negative (111). Nevertheless, the typical 
morphotypes of anaerobes are usually seen on Gram stain and the characteristic putrid 
odor of the pleural fluid is considered diagnostic of anaerobic infection. Often, there is 
deposition of a dense layer of fibrin on both the visceral and parietal pleurae that can lead 
to pleural loculation (112). Whether spontaneous adhesions of the pleural space can result 
from pleural space inflammation without infection is unknown. 
 
3. Thoracic empyema — Empyema develops when there is evident bacterial infection 
of the pleural liquid, resulting in either pus or the presence of bacterial organisms on 
Gram stain. A positive culture is not required for a diagnosis, since there are several 
reasons why bacteria may not be cultured from an empyema (see 'Bacteriology' below): 
● Anaerobic organisms may be difficult to culture or anaerobic cultures are not 
done because they are not specifically requested 
● Sampling is often performed after a patient has received antibiotics 
● Sterile inflammatory fluid may be aspirated adjacent to an infected loculus of 
infection 
● Current culture methods are insufficiently sensitive 
 
1.7.3 Clinical presentation 
The clinical presentation of the adult with parapneumonic effusion or empyema depends 
upon the patient's timing of presentation and immune competence, and also the specific 
organisms causing infection. Patients with pneumonia and uncomplicated parapneumonic 
effusion present earlier in the course of their pneumonia; those with empyema typically 
present later when bacteria from the untreated pneumonia have had time to colonize the 
pleural space. Infection with less virulent bacteria favors a later presentation; therefore, 
many empyemas complicate indolent anaerobic pneumonias, such as those following 
aspiration. 
Common clinical features of bacterial pneumonia with parapneumonic effusion include 
cough, fever, pleuritic chest pain, dyspnea, and sputum production. However, patients 
may only have one or two of these symptoms. In general, the presenting symptoms, other 




have pneumonia versus pneumonia with a parapneumonic effusion or empyema. 
Compared to those with pneumonia alone, patients with empyema may report a longer 
course with several days of fever and malaise rather than hours. Among patients with 
pneumonia, the presence of a parapneumonic effusion was associated with an increased 
likelihood of being admitted, a longer hospital stays, and possibly increased mortality 
(113). 
Physical examination may identify the presence of pleural fluid when the fine or coarse 
crackles, egophony (also known as e-to-a changes), and increased fremitus (palpable 
asymmetric increase in vibration with speech) typical of consolidation are replaced by 
decreased breath sounds and decreased fremitus. Occasionally, egophony will still be 
present at the upper edge of the effusion. Dullness to percussion is a potential feature of 
lung consolidation from either pneumonia or pleural effusion and is thus not a useful 
discriminating physical finding. Although clinical findings are helpful when present, they 
are often absent so radiographic imaging is crucial to the complete evaluation. 
Radiographic and ultrasound imaging play a key role in the evaluation and management 
of parapneumonic effusions and empyema (114). In all patients with pneumonia, the chest 
radiograph should be evaluated for evidence of pleural fluid. 
The presence of a complicated parapneumonic effusion or empyema is first suggested by 
a chest radiograph showing a pleural-based opacity. 
 
1.7.4 Epidemiology of parapneumonic effusion 
Pleural infection is rising in incidence across all age groups worldwide, confirmed by 
reports from the United States, Canda, Europe and Asia (115). The mortality rate of 
empyema has risen alarmingly. In Utah, death rates from empyema were sixfold higher 
in 2000-2004 compared to 1950-1975 (116). Overall in the United States, the incidence 
of empyema per 100,000 persons had roughly doubled between 1996 and 2008 with 
roughly equal increase occurring in all age groups (117). In this study, the increase was 
largely due to increase in nonpneumococcal empyema and Staph sp. empyema (55). The 
explanation for the increase in empyema incidence is not clear but has been attributed at 
least in part to the induction of the heptavalent pneumococcal conjugate vaccine (PCV7) 
IN 2000. After the introduction of this vaccine, there was a reduction in invasive 
pneumococcal disease, but the incidences of pneumococcal empyema in children and 




covered by the vaccine was overcompensated by an emergence of disease caused by 
nonvaccine serotypes (particularly serotype 1) (115). 
 
1.7.5 Diagnostic evaluation of a pleural effusion in adults 
Determining the cause of a pleural effusion is greatly facilitated by analysis of the pleural 
fluid. Thoracentesis is a simple bedside procedure with imaging guidance that permits 
fluid to be rapidly sampled, visualized, examined microscopically and quantified for 
chemical and cellular content. 
The indication for diagnostic thoracentesis is the new finding of a pleural effusion. 
Observation, in lieu of diagnostic thoracentesis, may be warranted in uncomplicated heart 
failure and viral pleurisy. In the former setting, the clinical diagnosis is usually secure; in 
the latter, there is typically a small amount of fluid. However, if the clinical situation is 
atypical or does not progress as anticipated, thoracentesis should be performed. 
Tests routinely performed on pleural fluid include cell count, pH, protein, lactate 
dehydrogenase (LDH), and glucose. Additional commonly performed tests in selected 
patients include amylase, cholesterol, triglycerides, N-terminal pro-BNP, adenosine 
deaminase, gram and AFB (acid-fast bacilli) stain, bacterial and AFB culture, and 
cytology. 
Initial diagnostic clues can be obtained by gross inspection of pleural fluid as it is being 
aspirated from the patient's chest (118). Observations that are helpful for diagnosis are 

















Table 4 – Colors of pleural fluid helpful in diagnosis (109). 
 
Color of fluid Suggested diagnosis 
Pale yellow (straw) Transudate, some exudates 
Red (bloody) Malignancy, benign asbestos pleural effusion, postcardiac 
injury syndrome, or pulmonary infarction in absence of trauma 
White (milky) Chylothorax or cholesterol effusion 
Brown Long-standing bloody effusion; rupture of amebic liver abscess 
Black Aspergillus niger, Rhizomes oryzae, metastatic melanoma, 
pancreaticopleural fistula, crack cocaine use, bronchogenic 
adenocarcinoma, chronic hemothorax 
Yellow-green Rheumatoid pleurisy 
Dark green Biliothorax 
 
The pleural fluid is next characterized as either a transudate or an exudate. 
 
Transudates — Transudates result from imbalances in hydrostatic and oncotic pressures 
in the chest, as occur with CHF and nephrosis, or conditions external to the pleural space. 
Examples of the latter include movement of fluid from the peritoneal, cerebrospinal, or 
retroperitoneal spaces, or from iatrogenic causes, such as crystalloid infusion through a 
central venous catheter that has migrated into the mediastinum or pleural space. 
Nevertheless, transudates have a limited number of diagnostic possibilities that can 














Table 5 - Causes of transudative pleural effusions (109). 
 
Transudate etiologies Comments 
Atelectasis Caused by increased intrapleural negative pressure 
Cerebrospinal fluid leak 
into pleural space 
Thoracic spinal surgery or trauma and ventriculopleural 
shunts 
Heart failure Acute diuresis can result in borderline exudative features 
Hepatic hydrothorax Rare without clinical ascites 
Hypoalbuminemia Edema liquid rarely isolated to pleural space 
Iatrogenic Misplaced intravenous catheter into the pleural space 
Nephrotic syndrome Usually subpulmonic and bilateral 
Peritoneal dialysis Acute massive effusion develops within 48 hours of 
initiating dialysis 
Urinothorax Caused by ipsilateral obstructive uropathy 
 
Exudates — In contrast, exudative effusions present more of a diagnostic challenge. 
Disease in virtually any organ can cause exudative pleural effusions by a variety of 
mechanisms (Table 6), including infection, malignancy, immunologic responses, 
lymphatic abnormalities, noninfectious inflammation, iatrogenic causes, and movement 
of fluid from below the diaphragm. 
Exudates result primarily from pleural and lung inflammation (resulting in increased 
capillary and pleural membrane permeability) or from impaired lymphatic drainage of the 
pleural space (resulting in decreased removal of protein and other large molecular weight 
constituents from the pleural space). Exudates can also result from movement of fluid 












Table 6 – Causes of exudative pleural effusions (109). 
 
Exudate etiologies Exudate etiologies descriptions 
Infectious Bacterial pneumonia, Tuberculous pleurisy, Parasites, Fungal 
disease, Atypical pneumonias, Subphrenic abscess, Hepatic 
abscess, Splenic abscess, Hepatitis, Spontaneous esophageal 
rupture 
Malignancy-related Carcinoma, Lymphoma, Mesothelioma, Leukemia, 




Lupus pleuritis, Rheumatoid pleurisy, Mixed connective tissue 
disease, Eosinophilic granulomatosis with polyangiitis (Churg-
Strauss), Granulomatosis with polyangiitis (Wegener's) 
Endocrine 
dysfunction 
Hypothyroidism, Ovarian hyperstimulation syndrome 
Other inflammatory 
disorders 
Pancreatitis (acute, chronic), Benign asbestos pleural effusion, 
Pulmonary embolism, Radiation therapy, Uremic pleurisy, 
Sarcoidosis,  Postcardiac injury syndrome, Hemothorax. 
Iatrogenic Drug-induced, Esophageal perforation, Esophageal 




1.7.6 Diagnostic criteria 
 The Light's Criteria Rule is a traditional method of differentiating transudates and 
exudates that measures serum and pleural fluid protein and LDH (119). Abbreviated 
versions of Light's Criteria Rule have similar diagnostic accuracy and have been 
recommended for clinical use (120-121). 
According to the traditional Light's Criteria Rule, if at least one of the following three 
criteria (ie, component tests of the rule) is fulfilled, the fluid is defined as an exudate 
(119): 
1. Pleural fluid protein/serum protein ratio greater than 0.5, or 




3. Pleural fluid LDH greater than two-thirds the upper limits of the laboratory's normal 
serum LDH 
Combining results of two or more dichotomous tests into a diagnostic rule, as done by the 
Light’s Criteria Rule, wherein only one component test result needs to be positive to make 
the rule result positive always increases sensitivity at the expense of decreasing specificity 
of the rule. As would be expected, therefore, the sensitivity of the Light’s Criteria Rule is 
higher than the sensitivity of each of the three component tests of the rule but the 
specificity of the rule is lower than its individual components. This tradeoff of higher 
sensitivity for lower specificity in the design of Light’s Criteria Rule is appropriate for 
evaluating pleural fluid because it is important that exudates not be missed, since they 
can have important prognostic implications. Some transudates, however, may be 
misclassified as an exudate because of the decreased specificity of the rule (122). 
Light's criteria have been criticized for including both the pleural fluid LDH/serum LDH 
ratio and the pleural fluid LDH (120) because they are highly correlated (120-123). 
Alternative diagnostic criteria also exist. A meta-analysis of eight studies (1448 patients) 
examined pleural fluid tests and found that several tests identified exudates with accuracy 
similar to those used in Light's criteria, but did not require concurrent measurement of 
serum protein or LDH (120). Proposed two-criteria and three-criteria diagnostic rules, 
which require one criterion to be met to define an exudate, include: 
 
Two-test rule 
1. Pleural fluid cholesterol greater than 45 mg/dL. 




1. Pleural fluid protein greater than 2.9 g/dL (29 g/L). 
2. Pleural fluid cholesterol greater than cholesterol 45 mg/dL (1.165 mmol/L). 
3. Pleural fluid LDH greater than 0.45 times the upper limit of the laboratory's normal 
serum LDH. 
The previous pleural fluid LDH cutoff point for differentiating between exudates and 
transudates in the traditional Light's criteria rule was 67 percent of (or 0.67 times) the 
upper limit of normal serum LDH. This has been changed to 45 percent, based on 




pleural fluid as exudates or transudates when values are near the cutoff points (119-
120,123). Thus, clinical judgment is required when evaluating patients with borderline 
test results (124). 
 
Chemical analysis — The measurement of pleural fluid protein, LDH, glucose, pH, 
cholesterol, triglycerides, and amylase can provide useful information. 
 
Protein — Most transudates have absolute total protein concentrations below 3.0 g/dL 
(30 g/L), although acute diuresis in heart failure can elevate protein levels into the 
exudative range (125-127). However, such patients have a serum to pleural fluid albumin 
gradient (the difference between the serum and pleural values) greater than 1.2 g/dL (12 
g/L), which correctly categorizes their effusions as transudates (127-128). Elevated blood 
N-terminal pro-brain natriuretic peptide (NT-proBNP) also supports the diagnosis of 
heart failure when Light’s criteria yield results in the exudative range (129). 
● Tuberculous pleural effusions virtually always have total protein concentrations above 
4.0 g/dL (40 g/L) (119). 
● When pleural fluid protein concentrations are in the 7.0 to 8.0 g/dL (70 to 80 g/L) 
range, Waldenström’s macroglobulinemia and multiple myeloma should be considered 
(130-131). 
 
LDH — The level of pleural fluid lactic dehydrogenase (LDH) is one of the key criteria 
for differentiating transudates and exudates. Several specific disease associations have 
been noted with pleural fluid protein and LDH levels: 
● Pleural fluid LDH levels above 1000 IU/L (with upper limit of normal for serum of 200 
IU/L) are characteristically found in empyema (102), rheumatoid pleurisy (132), and 
pleural paragonimiasis (133), and are sometimes observed with malignancy. 
● Pleural fluid secondary to Pneumocystis jirovecii pneumonia has the characteristic 
finding of a pleural fluid/serum LDH ratio greater than 1.0 and a pleural fluid/serum 
protein ratio of less than 0.5 (134). Urinothorax is another cause of elevated pleural fluid 
LDH associated with low pleural fluid protein levels (135). 
 
Glucose — A low pleural fluid glucose concentration (less than 60 mg/dL [3.33 
mmol/liter], or a pleural fluid/serum glucose ratio less than 0.5) narrows the differential 




1. Rheumatoid pleurisy   
2. Complicated parapneumonic effusion or empyema  
3. Malignant effusion            
4. Tuberculous pleurisy  
5. Lupus pleuritis      
6. Esophageal rupture             
All transudates and all other exudates have pleural fluid glucose concentration similar to 
that of blood glucose. 
The mechanism responsible for a low pleural fluid glucose depends upon the underlying 
disease. Specific examples include: 
1. Decreased transport of glucose from blood to pleural fluid with rheumatoid pleurisy 
(136-137) or malignancy (138). 
2. Increased utilization of glucose by constituents of pleural fluid, such as neutrophils, 
bacteria (empyema), and malignant cells (139). 
The lowest glucose concentrations are found in rheumatoid pleurisy and empyema, with 
glucose being undetectable in some cases. In comparison, when the glucose concentration 
is low in tuberculous pleurisy, lupus pleuritis, and malignancy, it usually falls into the 
range of 30 to 50 mg/dL (1.66 to 2.78 mmol/liter). 
 
PH — Pleural fluid pH should always be measured in a blood gas machine rather than 
with a pH meter or pH indicator paper, as the latter will result in inaccurate measurements 
(140-141). A pleural fluid pH below 7.30 with a normal arterial blood pH is found with 
the same diagnoses associated with low pleural fluid glucose concentrations (142). The 
pH of normal pleural fluid is approximately 7.60, due to a bicarbonate gradient between 
pleural fluid and blood (143). Thus, a pH below 7.30 represents a substantial 
accumulation of hydrogen ions. Transudates generally have a pleural fluid pH in the 7.40 
to 7.55 range, while the majority of exudates range from 7.30 to 7.45 (142). 
The mechanisms responsible for pleural fluid acidosis (pH <7.30) include: 
1. Increased acid production by pleural fluid cells and bacteria (empyema) (139,144). 
2. Decreased hydrogen ion efflux from the pleural space, due to pleuritis, tumor, or pleural 
fibrosis. Specific examples include malignancy (138), rheumatoid pleurisy and 
tuberculous pleurisy (136-137). 
A low pleural fluid pH has diagnostic, prognostic, and therapeutic implications for 




pleural fluid pH malignant effusion have a high initial positive yield on pleural fluid 
cytology. They also tend to have a shorter survival and poorer response to chemical 
pleurodesis than those with a pH >7.30, although the strength of these associations do not 
provide prognostic value for individual patients (146-148). Clinicians should not use the 
pleural fluid pH as the sole criterion for the decision to recommend pleurodesis. 
A parapneumonic effusion with a low pleural fluid pH (≤7.15) indicates a high likelihood 
of necessity for pleural space drainage (table 5) (149-150). 
 
Nucleated cells — The total pleural fluid nucleated cell count is virtually never 
diagnostic. There are, however, some settings in which the count may be helpful: 
●Counts above 50,000/microL are usually found only in complicated parapneumonic 
effusions, including empyema. 
●Exudative effusions from bacterial pneumonia, acute pancreatitis, and lupus pleuritis 
usually have total nucleated cell counts above 10,000/microL (109). 
●Chronic exudates, typified by tuberculous pleurisy and malignancy, typically have 
nucleated cell counts below 5000/microL (109). 
The timing of thoracentesis in relation to the acute pleural injury determines the 
predominant cell type. The early cellular response to pleural injury is neutrophilic. As the 
time from the acute insult lengthens, the effusion develops a mononuclear predominance 
if the pleural injury is not ongoing. 
 
Lymphocytosis — Pleural fluid lymphocytosis, particularly with lymphocyte counts 
representing 85 to 95 percent of the total nucleated cells, suggests tuberculous pleurisy, 
lymphoma, sarcoidosis, chronic rheumatoid pleurisy, yellow nail syndrome, or 
chylothorax (118,151). Carcinomatous pleural effusions will be lymphocyte-predominant 
in over one-half of cases; however, the percentage of lymphocytes is usually between 50 

































(>10 mm and 
<1/2 
hemithorax) 
Neg culture and 
Gram stain¥¥ 












or Gram stain 
PH <7.20 Moderate Yes 
pus High Yes 
* pH is the preferred pleural fluid chemistry test, and pH must be determined by a blood gas analyzer. If a 
blood gas analyzer is not available, pleural fluid glucose should be used (P0 = glucose ≥60 mg/dL; P1 = 
glucose <60 mg/dL). The expert panel cautions that the clinical utility and decision thresholds for pH and 
glucose have not been well-established. 
** Repeat thoracentesis should be considered if effusion enlarges and/or clinical condition deteriorates. 
*** Larger effusions are more resistant to effective drainage, possibly because of the increased likelihood 
that large effusions will also be loculated. 
¥ Clinical experience indicates that effusions of this size do not require thoracentesis for evaluation, but 
will resolve. 
¥¥ Regardless of prior antibiotic use. 
†† If clinical condition deteriorates, repeat thoracentesis and drainage should be considered. 





1.7.7 Challenges in diagnosis of parapneumonic effusion 
The existence of inadequate diagnostic criteria is a major reason for a delay in diagnosis. 
Pleural leukocyte counts, effusion cells, differential counts and Light's criteria do not 
reliably identify an infectious etiology (110). Although a pleural pH <7.20 and pleural 
glucose <60 mg/dL are indications for pleural drainage, these thresholds are not 
sufficiently sensitive (151). Moreover, other conditions, such as malignancy, 
tuberculosis, rheumatoid pleurisy, and lupus pleuritis, can cause pleural fluid acidosis or 
low pleural glucose, demonstrating that these indicators lack specificity for infection 
(152). Although a pleural white blood cell count >50,000 cells/µL may help accurately 
diagnose parapneumonic effusions, pleural white cell counts more often range between 
10,000 to 50,000. As a result, they are not sensitive for diagnostic purposes (153). 
Although microbiologic studies provide definitive evidence of infection, positive cultures 
are seen in only 60% of parapneumonic effusions, and there is often a prolonged time to 
culture positivity (154-155). 
Because the classic pleural biochemistry testing lacks both sensitivity and specificity, the 
development of a novel pleural biomarker for infection has been an area of active 
investigation. Procalcitonin, interferon-ɣ, carcinoembryonic antigen, interleukin-6, tumor 
necrosis factor-α and soluble triggering receptor expressed on myeloid cells 1 (STREM-
1) have been evaluated for their utility in distinguishing empyema from other types of 
effusions, but they are not sensitive for detection (155-157). 
 
1.7.8 Pleural CRP for parapneumonic effusion identifying 
CRP was discovered in Oswald Avery’s laboratory during the course of studies of patients 
with Streptococcus pneumoniae infection (158). CRP is an acute phase protein that is 
synthesized by the liver in response to various stimuli (159). The induction of CRP 
synthesis in the liver is triggered by the production of IL-6 and TNF-α by local pleural 
cells (160-161). The pleural fluid CRP levels are likely to reflect the serum levels because 
the presence of CRP in the pleural fluid may be due to increased diffusion from the blood 
as a result of inflamed capillary leakage (160-161).  
Pleural CRP has recently been proposed as a specific biomarker for the differential 
diagnosis of pleural effusions and reportedly exhibits higher sensitivity and specificity 
than serum CRP (162). CRP can be considered a good candidate due to its 1000-fold 




pleural CRP levels (163-164). However, few studies with limited samples sets have been 







































2.1- Bacterial distribution profile in bronchiectatic patients 
There are several points which the guideline does not address 
1) By consideration of empiric therapy in patient with no previous bacteriology, the 
guideline does not take in consideration certain risk factors: patient age, 
bronchiectasis location, disease patter (bilateral vs unilateral). 
2) The guideline generally recommends on taking routinely sputum bacteriology 
but do not make special subgroup that prone to certain infections. 
Thus, the aims of this study were to assess in bronchiectatic patients with infective 
exacerbations the following clinical parameters: 
1) The direct influence of patient age on bacterial profile 
 2) Characterize the lobar bacterial distribution of the bronchiectasis 
 3) Report the resistance rates of P. aeruginosa and H. influenzae 
4) Explore the isolation rate of NTM. 
 
2.2 Role of CRP in detecting parapneumonic effusion 
We have very good criteria for defining empyema (pus appearance, pleural glucose<60, 
pleural PH<7.2) but with less usefulness for early detection of parapneumonic effusion 
before it becoming complicated.  
Thus, the second aims of this study were: 
1) Evaluating the sensitivity and specificity of pleural CRP levels in diagnosing 
parapneumonic effusions  
2) Looking for the role of pleural CRP levels in distinguishing exudative from 
transudative effusions.  














3.1 Study subjects of bronchiectasis bacterial distribution research 
A retrospective cohort study of 339 individuals with a diagnosed infectious exacerbation 
of bronchiectasis occurring between January 2006 and December 2014 was conducted at 
the Rabin Medical Center (RMC), PetachTikva, Israel.  
The criteria for inclusion in the study were as follows: 
 1) Diagnosis of bronchiectasis established by high-resolution computed tomography 
(HRCT) within <1 year before entry into the study (168). 
 2) Acute infectious exacerbation of bronchiectasis.  
3) Performance of a bronchoalveolar lavage (BAL) and bacterial cultures.  
Medical charts were analyzed for demographic data, clinical and radiological reports, and 
microbiologic information. We reviewed the results of the BAL cultures and HRCT to 
characterize the bronchiectasis lobar distribution. The BAL culture results were organized 
into 9 groups: no bacteria (or "normal flora"), H. influenzae, Staphylococcus aureus, 
Streptococcus pneumoniae, other Streptococcus species (Groups A-F), P. aeruginosa, 
NTM, Enterobacteriaceae (Escherichia coli, Klebsiella,Proteus, Enterobacter, Serratia) 
and others (Moraxella catarrhalis, Stenotrophomona smaltophilia and Acinetobacter 
species). The patient population was divided into 2 groups to compare the distribution of 
the BAL culture results according to age, using the sample median age as the groups' 
separation line. The lobar distribution of bronchiectasis in the population sample and the 
bacterial distribution prevalence in each pulmonary lobe were also mapped. Each 
bacterial presentation in bilateral disease (both lung-diffuse distribution) was analyzed 
and compared to unilateral (one lung-local distribution) bronchiectatic disease. Finally, 
antibiotic susceptibility testing was performed for all isolated bacteria.  
 
3.2 BAL procedure 
The patient was placed in the supine position for fiberoptic bronchoscopy and nasal 
oxygen was administered at 2–4 liters per minute. Patients received topical anesthesia 
with lidocaine, intravenous (IV) alfentanil 0.5 mg, and intermittent boluses of IV 
midazolam. No other sedating or hypnotic agents were used in this study. The fiberoptic 
bronchoscope (BF-1T240 Video Bronchoscope, Olympus Corporation, Tokyo, Japan; or 




and advanced to target subsegmental bronchi. The BAL trap used to collect the specimen 
was connected to the suction channel of the bronchoscope only once distal of the vocal 
cords. Suction was avoided until the bronchoscope had traversed the vocal cords to avoid 
contamination by upper airway flora. The fiberoptic bronchoscope was wedged into a 
subsegmentary bronchus that was closest to the suspected infected lobe by radiology (e.g 
the lateral subsegment of right middle lobe (RML) bronchus or the superior subsegment 
of the lingular bronchus), and three aliquots of sterile saline (50 mL each) were instilled 
and aspirated. The first aliquot was discarded. The mean BAL fluid obtained for 
processing was 30 ± 10 ml. 
 
3.3 Microbiologic samples 
BAL samples were plated on blood agar, chocolate agar and MacConkey agar. All 
specimens were analyzed for mycobacteria using Ziehl-Nielsen stain and were cultured 
on Lowenstein medium and in Mycobacterium Growth Indicator Tubes (BACT MGIT 
960, Becton Dickinson, USA). Negative bacterial cultures were discarded after 7 days, 
whereas MGIT and Lowenstein-Jensen cultures were discarded after 6-8 weeks. We used 
GenoType Mycobacterium DNA strip assay (HainLifescience GmbH, Nehren, Germany) 
for the detection and identification of mycobacteria species which were obtained from 
positive liquid and solid mycobacterial cultures. Susceptibility testing was performed 
using the National Committee for Clinical Laboratory Standards (169). Antimicrobial 
susceptibility testing was performed using Oxoid disks (Thermo Scientific, UK) and E 
tests (bio-Merieux, Marcy-L Etoile, France). 
The study received ethical approval by the Helsinki Committee of the Rabin Medical 
Center Petach Tikvah, Israel. 
 
3.4 Study subjects of pleural CRP research 
A retrospective, single-cohort study of clinically significant pleural effusions was 
performed at the Rabin Medical Center in Petach Tikva, Israel. The inclusion criteria in 
the study were as follows:  
1) Ambulatory patients who were under outpatient observation at the Rabin Medical 
Center Pulmonary Institute and were diagnosed with a new pleural effusion  
 2) Hospitalized patients who were referred for pulmonary consultation from internal 




The study population consisted of 244 individuals who were treated at our institution 
between January 2011 and December 2013. The diagnoses were divided into five 
categories on the basis of the underlying disease. 
  
3.5 Definitions of different types of pleural effusions 
The diagnosis of malignant effusion was made when malignant cells were found on 
pleural fluid cytologic examination or in a biopsy specimen. 
The pleural effusion was considered parapneumonic when it was associated with acute 
febrile illness with purulent sputum, pulmonary infiltrate responsive to antibiotic 
treatment or when a microorganism was identified in the pleural fluid. Empyema was 
defined as a thick, purulent appearing of parapneumonic effusion. 
Tuberculous pleural effusion was diagnosed based on positive cultures for 
mycobacterium tuberculosis or when the pleural biopsy specimen revealed typical 
epithelioid cell granulomas. 
The effusion was attributed to congestive heart failure (CHF) in individuals with findings 
of an enlarged heart, radiographic pulmonary venous congestion, and peripheral edema 
responding to diuretic treatment in the absence of malignancy or pulmonary infiltrates 
associated with an inflammatory process. 
The diagnosis of post-lung transplantation pleural effusion was made in patients who had 
undergone recent lung transplantation and lacked evidence of malignancy, infection or 
rejection. 
 
3.6 Laboratory Studies 
Pleural fluid samples were obtained with thoracentesis before treatment soon after the 
diagnosis of pleural effusion. Samples were analyzed for total differential cell counts, 
CRP, glucose, total protein, lactate dehydrogenase (LDH), pH, amylase and cholesterol. 
Additionally, cytologic examination and bacterial cultures using blood agar, chocolate 
agar and MacConkey agar, Lowenstein medium, and Mycobacterium Growth Indicator 
Tubes (BACT MGIT 960, Becton Dickinson, USA) were routinely obtained for all 
pleural fluid samples. All specimens were analyzed for mycobacteria using Ziehl-Neelsen 
stain. 
The supernatant was obtained by centrifugation at 300 rpm for 15 min and stored at -20°C 
until assayed. The clinicians who performed the laboratory studies were blinded to the 




CRP analysis was performed on a Beckman Coulter AU 2700 analyzer using a particle-
enhanced immue-turbidimetric method and latex particles coated with monoclonal anti 
CRP antibodies. The test is linear within a concentration range of 0.008-8 mg/dl. The 
CRP reference range values were 0-0.5 mg/dl. 
 
3.7 Statistical analysis  
Data were collected retrospectively. Descriptive data were expressed as the mean and 
standard deviation (SD) or number of patients (n) and percentage (%). The differences 
between bacterial profiles according to age were examined using the Fisher exact test 
(Table 1). Statistical significance was set at p<0.05. A univariate logistic regression 
analysis was performed to determine the relationship between each bacterial infection and 
patient age.  
To determine the variables that were most significantly associated with parapneumonic 
effusion, we included all pleural parameters that were traditionally used to indicate the 
type of effusion (PH, LDH, glucose, neutrophils, CRP) in a backward stepwise logistic 
regression. 
To evaluate the diagnostic performance of CRP, as a marker for differentiating between 
parapneumonic effusions and other pleural effusions, receiver operator characteristics 
(ROC) analysis was performed for all significant differences between groups. ROC 
curves were generated by plotting the sensitivity against 1-specificity, and the area under 
the curve (AUC) with 95% confidence intervals (95% CI) was calculated. The optimum 
cut-off point based on the ROC analysis was established by selecting the value that 
provides the greatest sum of the sensitivity and specificity, i.e., the point closest to the 
upper left point of the ROC plot. For the optimum cut-off point provided by each ROC 
analysis, the sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) were calculated using standard formulas.  To calculate the ROC 














4.1 BAL bacterial isolation   
A total of 339 patients were identified as having NCFBr, with a median age of 64 years 
(Table 8). Of the sample population, 133 (39%) were males and 206 (61%) were females, 
a 1:2 relation. 319/339 (94%) underwent a single BAL procedure while 20/339 (6%) 
underwent a repeated second procedure during the study period.  
 
Table 8 - BAL microbiologic profile in patients according to age. 
P value 
Age >64 years 
(N = 162; 66 
male) 
% (n) 
Age ≤ 64 years 
(N = 177; 67 male) 
% (n) 
 
NS 40.7% (66) 37.8% (67) No bacteria 
0.0001>  9.2% (15) 25.4% (45) Haemophilus influenzae 
NS 10.4% (17) 10.1% (18) Staphylococcus aureus 
NS 3% (5) 5.6% (10) Streptococcus pneumonia 
NS 6.1% (10) 6.7% (12) Other Streptococcus species 
0.05 17.2% (28) 9.6% (17) Pseudomonas aeruginosa 
NS 10.4% (17) 6.7% (12) 
Non-tuberculous 
mycobacterium 
NS 9.2% (15) 4.5% (8) Enterobacteriaceae 
NS 
61.7% (100) /  
38.3 (62) 
59.4% (105) /  
40.6% (72) 
Unilateral / Bilateral 
 
On initial assessment of 387 BAL culture results, 65.6% were positive for pathogenic 
microorganisms; the remainder yielded no bacteria (normal flora) (Table 9). The most 
common organisms were H. influenzae in 60 patients (15.5%), P. aeruginosa in 45 
(11.6%) and S. aureus in 35 (9%). Less common organisms included NTM in 29 patients 
(7.5%), Enterobacteriaceae in 23 (5.9%), Streptococcus species in 22 (5.7%) and S. 
pneumoniae in 15 (3.9%). Of the total culture results, 25 (6.5%) were defined as "other" 
















During the study period, BAL collection was performed twice on 20 patients, of which 9 
samples (yellow color) revealed the same results in both cultures (Table 10). 
 




Second BAL First BAL Patient 
number 
12 No bacteria H. influenzae 1 
10 No bacteria No bacteria 2 
24 P. aeruginosa Stenotrmaltophila 3 
9 Escherichia coli Escherichia coli 4 
8 Mycobacterium 
simiae 
Mycobacterium simiae 5 
22 No bacteria No bacteria 6 
34 H. influenzae No bacteria 7 
49 Klebsiellaoxytoca No bacteria 8 
5 H. influenzae Streptococcus gr b 9 
27 No bacteria No bacteria 10 
36 einfluenzaH.  eH. influenza 11 
15 No bacteria Acinetobacter sp 12 
2 Mycobacterium 
intracellulare 
Streptococcus sp 13 
22 P. aeruginosa P. aeruginosa 14 
25 No bacteria No bacteria 15 
11 Staph aureus No bacteria 16 
34 No bacteria H. influenzae 17 
29 Staph aureus Staph aureus 18 
12 P. aeruginosa No bacteria 19 
7 No bacteria H. influenzae 20 
 
 
Percentage of positive cultures (n) Type of Bacteria 
34.4% (133) No bacteria 
15.5% (60) Haemophilus influenzae 
11.6% (45) Pseudomonas aeruginosa 
9% (35) Staphylococcus aureus 
7.4% (29) Non-tuberculous mycobacterium 
6.5% (25) Others 
5.9% (23) Enterobacteriaceae 
5.7% (22) Other Streptococcus species 
3.9% (15) Streptococcus pneumoniae 




4.2 BAL isolation according to age 
Univariate analysis revealed a significantly higher frequency of H. influenzae in the 
younger age group (25.4% in ≤64 years group vs. 9.2% in >64 years group, p<0.001). By 
contrast, P. aeruginosa was found at a significantly higher frequency in those aged >64 
years compared with the younger patient group (17.2% vs. 9.6%, respectively, p=0.05). 
There was also a higher but not statistically significant frequency of NTM (10.4% >64 
years vs. 6.7% ≤64 years) and Enterobacteriaceae (9.2% >64 years vs.4.5% ≤64 years) 
detected in the older age group.  
Univariate logistic regression showed a similar pattern, whereby the frequency of H. 
influenzae was higher in younger patients (OR=0.969, p<0.0001, 95% CI 0.954-0.983), 
whereas the frequencies of P. aeruginosa (OR=1.027, p=0.008, 95% CI 1.007-1.048) and 
Enterobacteriaceae (OR=1.039, p=0.01, 95% CI 1.009-1.069) were much higher in older 
patients (Table 11). 
 
Table 11 - Univariate logistic regression of H. influenzae, P. aeruginosa and 
Enterobacteriaceae odds ratio (OR) according to age. 
 
 
4.3 Non-tuberculous mycobacterium (NTM) 
NTM were isolated in 6.3% (29/339) of the study sample, which increased in prevalence 
to 10.4% (17/162) in the >64 years of age group. These NTM included Mycobacterium 
avium-intracellulare (n=14), M. simiae (n=8), M. abscessus (n=3), M. chelonae (n=2) 
and M. fortuitum (n=2). 
The lobar distribution of NTM in all patients was as follows: 22.9% in the right upper 
lobe (RUL), 22.5% in the RML, 18.31% in the lingula, 14% in the right lower lobe (RLL), 







4.4 Lobar bronchiectasis distribution  
There was no significant difference between the lobar distributions of bronchiectasis in 
the younger versus the older group (Table 1). 
The general lobar distributions of bronchiectasis in all 339 patients were as follows: 
25.9% in the RML, 20.7% in the RLL, 20.4% in the LLL, 13.8% in the lingula, 13% in 
the RUL, and 6.2% in the LUL. 
 
4.5 Lobar bacterial distribution in bronchiectasis  
In the LLL, RLL, and RML of the lung, the most frequent pathogen was H. influenzae 
(23% - 28% of the total bacterial species in each lobe), and the second most common 
bacterial species was P. aeruginosa (19% - 21% in each lobe; Figure 7). In the lingula, 
H. influenzae comprised 14% and NTM comprised 13% of all bacterial species in this 
lobe. In the RUL, the most common bacterial species was P. aeruginosa, and the second 
most common was NTM, at prevalence rates of 18% and 17%, respectively. Finally, in 
the LUL, the most prevalent bacterial species were NTM, and the second most common 
was P. aeruginosa (9% and 6% of the total lobe's bacterial species, respectively).  
 
 
Figure 7- Lobar bacterial distribution in bronchiectatic patients. The prevalence of each 
bacterium is represented in each lobe. RUL, right upper lobe; RML, right middle lobe; 





NTM was found to have a significantly higher prevalence in bilateral versus unilateral 
bronchiectasis (65.5% [19/29] vs.34.4% [10/29], respectively, p=0.004). The other 
bacterial groups showed no statistically significant differences in their prevalence when 
comparing unilateral and bilateral disease (Table 12). 
 
Table 12 - Bacterial distribution - unilateral versus bilateral bronchiectasis disease. 
 
P value Unilateral bronchiectasis Bilateral 
bronciectasis 
Type of bacteria 
NS* 60.5% (81) 39.1% (52) No bacteria 
NS 61.6% (37) 38.3% (23) Haemophilus influenzae 
NS 51.5% (17) 48.4% (16) Staphylococcus aureus 
NS 53.3% (8) 46.6% (7) Streptococcus pneumoniae 
NS 55.5% (25) 44.4% (20) Pseudomonas aeruginosa 
0.004 34.4% (10) 65.5% (19) Non Tuberculus 
Mycobacteria 




4.6 Resistance to antibiotics 
In this study, we reviewed the antibiotic sensitivity results of the two largest bacterial 
groups: H. influenzae and P. aeruginosa. A total of 60 isolations of H. influenzae were 
observed; of these, 18.3% (11/60) showed resistance to sulfamethoxazole/ trimethoprim, 
16.7% (10/60) to ampicillin and 1.7% (1/60) to ciprofloxacin. No resistance to 
cephalosporins, tetracycline or ertapenem was observed. 
Of a total of 45 isolations of P. aeruginosa, 17.8% (8/45) showed resistance to 
ciprofloxacin, 6.7% (3/45) to gentamicin and amikacin, 4.4% (2/45) to piperacillin and 
2.2% (1/45) to imipenem and ceftazidime; none showed resistance to tazocin and colistin. 
 
4.7 Pleural effusion distribution 
Of the 244 patients classified as having pleural effusions, 180 (73.7%) were diagnosed 
with exudative effusion, 44 (18%) were diagnosed with transudative effusion and 20 
(8.1%) were excluded from the study due to lack of definitive diagnosis. The exudative 
effusion group was further divided into the following three subgroups according to the 




(10.2%) lung transplant recipients (Table 13). Tuberculous pleural effusion was not 
diagnosed in any patient. 
 




4.8 Pleural CRP level in pleural effusions 
The pleural CRP levels differed significantly among all four groups (p<0.001). The mean 
values from highest to lowest were as follows: parapneumonic (5.38±4.85 mg/dl), lung 
transplant (2.77±2.66 mg/dl), malignancy (1.19±1.51 mg/dl) and heart failure (0.57±0.81 
mg/dl) (Figure 8). A backward logistic regression model selected CRP as the only 









Heart failure Malignancy  





0.02 15 60% 50 77.3 52.9 Male, (%) 
0.001>  58.3±6.4 59.5±19.7 64 ±17.9 76.2±10.6 70.9±12 Age, years 
0.01=  715.2±259.9 681.6±439.5 983.4±552.6 1380.6±668.2 1514.4±1694.5 Amount, ml  
0.001>  2.77±2.66 9.06±6.72 5.38±4.85 0.57±0.81 1.19±1.51 CRP level, mg/dl 
0.003=  9.13±21.82 2.2±1.1 1.59±1.84 0.81±1.05 2.49±7.56 WBC, K/micL 
0.01 22.33±24.53 44.3±40 30.5±26.3 17.86±11.86 21.31±15.48 Neutrophils, % 
NS 60.99±30.09 30.1±30 44.92±28.19 51.33±23.27 51.79±23.97 Lymphocyte, % 
NS 0.64±1.05 0.76±1 1.83±2.92 0.99±1.08 1.38±2.25 Eosinophils, % 
0.001>  82.09±37.44 69±26.9 59.63±33.64 36.9±18.77 74.64±33.58 Cholesterol, 
mg/dl 
NS 33.55±20.96 68.4±79 34.95±33.21 21.1±16.37 47.92±186.24 Triglyceride, 
mg/dl 
NS 133.7±63.75 68±58.7 113.74±55.27 133.24±41.22 116.93±51.35 Glucose, mg/dl 
0.001>  3.51±0.84 3.98±0.96 3.22±1.16 3.07±1.05 4.31±1.06 Total protein, g/dl 













Figure 8 -Pleural fluid CRP levels in effusions secondary to pneumonia, malignancy, 
post-lung transplantation and heart failure. Each point represents one pleural fluid 
sample. The red points represent patients with empyema. 
 
To determine the efficiency of pleural fluid CRP measurement in distinguishing 
parapneumonic effusion from the other 3 groups, we used ROC analysis (Figure 9A). A 
CRP cut-off value of 1.38 mg/dl yielded 84.2% sensitivity, 71.5% specificity, 37.6% 
positive predicted value and 95.6% negative predicted value. Although the area under the 
curve (AUC) of the pleural CRP was as high as 0.85 (Figure 9A), it was lower for the 
following other pleural parameters: glucose (0.54), pH (0.61), neutrophils (0.59) and 





Figure 9 - Receiver operator characteristic (ROC) analysis curves of pleural fluid CRP 
levels for differentiating between different effusion types. 
9 (A) - ROC curve of CRP levels for differentiating parapneumonic pleural effusions 
from other types of pleural effusions such: malignant, heart failure and post-lung 
transplantation. 
9 (B) - ROC curve of CRP levels for differentiating between parapneumonic and 
malignant effusions. 
 
Figure 9 (C) - ROC curve of CRP for differentiating between parapneumonic and heart 




Figure6 (D) ROC curve of CRP for differentiating empyema from other types of 
effusion such: malignant, heart failure and uncomplicated parapneumonic pleural 
effusions 
 
CRP was a good marker for distinguishing parapneumonic effusion from: post-lung 
transplantation effusion (1.93 mg/dl cut-off value, 75% sensitivity, 56% specificity); 
malignant effusion (0.88 mg/dl cut-off value, 87% sensitivity, 64% specificity- Figure 
9B) and heart failure effusion (0.49 mg/dl cut-of value, 93% sensitivity, 72% specificity- 
Figure 9C).  
CRP was a moderately good marker for differentiating between empyema and other types 
of effusions (2.31 mg/dl cut-off value, 83.3% sensitivity, 74.7% specificity, 8.3% positive 
predictive value and 99.3% negative predictive value- Figure 9D) 
We also determined the efficiency of pleural fluid CRP measurements in distinguishing 
among heart failure effusion and the other 3 groups (Table 14). Using a cut-off value of 
0.64 mg/dl, CRP exhibited 79.5% sensitivity, 59.4% specificity, 32.4% PPV and 92.4% 
NPV. 
 
Table 14 - Receiver operating characteristic curve analysis of the accuracy of biomarkers 




Pleural white blood cells counts were significantly different among all four groups 
(p=0.003) with the following means: 9.13±21.82K/micL (lung transplant), 
2.49±7.56K/micL (malignancy), 1.59±1.84K/micL (parapneumonic) and 




Pleural neutrophil differentials were also significantly different among all four groups 
(p=0.01): 30.5±26.3% (parapneumonic), 22.33±24.53% (lung transplant), 21.31±15.48% 



































5. Discussion  
 
 
5.1 Lobar bacterial distribution in NCFBr 
In this retrospective cohort study of 339 individuals with infectious exacerbations of 
NCRBr, we found H. influenzae to be a more frequently associated bacterial pathogen in 
younger patients, whereas P. aeruginosa, NTM and Enterobacteriaceae were more 
frequently observed in the older age group. Previous studies have shown that P. 
aeruginosa pathogen carriage is associated with earlier diagnosis (54), lower FEV1, 
polymicrobial colonization (170), poorer quality of life and more hospital admissions 
(65). Moreover, it is possible that the older patients had a longer hospital stay, longer 
duration of the disease and more serious lung damage; however, because this study was 
retrospective in nature, this information was not available.  
The H. influenzae prevalence in our general sample was 15.2%, and it increased to 25.4% 
in the younger patient group. The frequency of this pathogen has been reported to range 
from 14% to 52% in patients with NCFBr in prior studies (53-55). Studies using a 
protected specimen brush have confirmed the presence of H. influenzae in the distal 
airways (54), although it is still possible that this organism represents oral contamination. 
We also found that (9/20) 45% of patients showed the same pathogen on repeat BAL 
analysis as in the initial study. This finding is supported by previous reports by Pasteur et 
al. (40) and King et al. (53), who found that 66% and 50% of subjects with bronchiectasis 
were colonized with similar bacteria when checked over 1- and 5-year periods, 
respectively. By contrast, McDonnell et al. (170) reported that 45% of patients with 
previous positive cultures for P. aeruginosa had subsequent negative cultures, most likely 
as a result of effective treatment of the bacterial infection. Based on these previous 
studies, one may conclude that previous BAL bacteriologic identification may be useful 
in determining which antibiotic to utilize for treatment.  
Our study also showed a high prevalence of NTM as a potential bacterial pathogen in 
subjects with infectious exacerbations of NCFBr. We found an increased prevalence of 
NTM in older patients, reaching as high as 10% of the total lung bacteria in patients > 64 
years of age; in comparison, other studies have reported NTM to represent up to 6% of 
the pathogenic profile in bronchiectatic patients (40, 55, 74). We suspect that the 
prevalence of NTM in bronchiectasis may be even higher, as attempts of NTM cultures 




be performed more frequently. Consideration should also be given to providing 
surveillance screening for NTM when treating patients >64 years of age, especially 
individuals showing a diffuse bronchiectatic pattern on HRCT examination.    
We also performed a study of antibiotic resistance among P. aeruginosa and H. influenzae 
isolates from patients with infectious exacerbations of bronchiectasis. For both bacteria, 
we did not find pan-resistance or multi-resistant strains. The highest resistance rate for P. 
aeruginosa isolates was to quinolone (17.8%), perhaps reflecting its widespread use. The 
resistance to alternative drugs such ceftazidime and carbapenem was very low, and no 
resistance was found to colistin and tazocin. Very high resistance rates for H. influenzae 
isolates to sulfamethoxazole/trimethoprim and ampicillin were found, which we speculate 
might be associated with frequent use of these antibiotics and longer hospitalization in 
our institution however this data was not available to us for analysis. 
This study had a number of limitations, most of which derive from its observational 
design. Many of the individuals included in the study were receiving care in the 
pulmonary clinics of the hospital. The inclusion requirements of our study, which 
included previous HRCT and concurrent BAL isolation, precluded the inclusion of 
individuals not under the care of the pulmonary staff. The study conclusions, therefore, 
may not be generalizable to groups of patients treated by other hospital staff members. 
Second, we cannot entirely assume that microbiologic samples isolated from different 
lobes truly represent the bacteriological population in the sampled lobe, as they may 
instead represent bacterial colonization. Nonetheless, it may be expected that the areas of 
bronchiectatic lung are the most likely areas to develop acute infection. BAL isolation is 
a procedure that may readily provide reliable samples for culture; furthermore, this 
technique is associated with few complications and is readily available at our center. 
The strengths of this study include the following. First, we included a large sample of 
bronchiectatic patients. Second, our analysis of BAL culture results provided an accurate 
representation of the flora of the distal airways, whereas sputum samples represent more 









5.2 The role of pleural CRP in parapneumonic effusion detection 
The present study provides evidence for the utility of the pleural fluid CRP measurement 
in diagnosing parapneumonic effusions. Early recognition of this diagnosis prevents 
possible adverse consequences from an untreated infection of the pleural cavity. We 
found that the pleural CRP levels were higher in parapneumonic effusion than in other 
effusion types, with a cut-off value of > 1.38 mg/dl. At this cut-off level, we found a low 
PPV but very high NPV, which implies a modest utility in confirming the diagnosis but 
a powerful tool for excluding it. The same is true with empyema, due to its high NPV, a 
cut-off value below 2.31 can theoretically decrease the necessity of pleural drainage for 
complicated effusions.  Our results are consistent with other studies that reported higher 
CRP levels in parapneumonic effusions among the exudative categories, which exhibit a 
range of cut-off values of 3 to 9 mg/dl (109, 156-157,162,166). The differences in the 
absolute cut-off values can be attributed to the different analysis methods used for 
measuring CRP. Moreover, when the underlying cause of a pleural effusion is obscure, a 
high pleural CRP level combined with pleural neutrophil predominance, lower pleural 
glucose and lower pleural pH may shift the diagnosis towards an infectious etiology. 
This study corroborates and amplifies previous investigations. Pleural CRP levels are 
reportedly higher in parapneumonic effusions than in other types of exudates 
(109,162,166). Evaluation of the pleural CRP levels is a useful test for differentiating 
between complicated and uncomplicated parapneumonic effusions (156,165) and 
between acute and chronic inflammation (166). Kapisyzi et al (171) observed that the 
sensitivity of pleural CRP levels was higher than serum CRP levels in distinguishing 
transudative from exudative effusions as well as malignant from benign effusions. A 
prospective evaluation of seven biological markers in patients with different causes for 
exudative effusions demonstrated that CRP provides the largest AUC (0.92) for 
distinguishing between parapneumonic effusions and tuberculosis or malignant effusions 
(167). Kriopoulos et al and Gabhale et al reported that pleural CRP levels provided 
excellent sensitivity (100%) and good specificity (79, 98.8%) at cut-off levels of 5.3 and 
9.08 mg/dl, respectively, for differentiating between parapneumonic effusion and 
tuberculosis or malignant effusions (109, 166). A few investigative reports have 
suggested that the combination of pleural fluid CRP levels with neutrophil count (156, 
167) or adenosine deaminase (157) to be superior to pleural CRP levels alone for 




Finally, in addition to exhibiting diagnostic value, pleural CRP levels exhibit prognostic 
value and can serve as a supporting tool for drainage. Porcel at al (156) found that CRP 
levels >10 mg/dl were associated with complicated parapneumonic effusion and were 
associated with the need for pleural effusion drainage. Moreover, the combination of 
classical biomarkers (pleural pH <7.2, LDH>100 IU/dl, glucose<60 mg/dl) improves the 
accuracy of detecting parapneumonic effusion (156,165). 
We also found that WBC counts were higher in pleural effusion post transplantation that 
in parapneumonic group. Moreover, in both groups the main pleural cell differential was 
lymphocyte. The explanation for post transplantation pleural lymphocytosis is disruption 
of lymphatic flow due to severance of allograft lung lymphatics (172).   
The main strengths of this study are that it demonstrates the diagnostic value of pleural 
CRP measurements in a large cohort of patients with varying etiologies for pleural 
effusion. Second, although we used several markers of inflammation individually or in 
combination with CRP, only CRP as a single biomarker had the highest sensitivity and 
specificity in differentiating between parapneumonic effusions and other effusion types. 
Finally, for every thoracentesis performed in this study, the same pleural biomarker panel 
was collected, decreasing the probability of selection bias. 
A limitation of the present study is its retrospective, single-center design. A second 
limitation is the inclusion requirement utilizing only hospitalized or ambulatory patients 
under medical observation of pulmonologists necessarily excluding individuals under the 
care of general physicians. A third limitation is the lack of serum CRP level data which 
could serve for control and comparison analysis. A fourth limitation is the inability to 
explore the CRP trend changing level during the progression/resolving of the 
parapneumonic effusion, due to the availability of a single point measurement of pleural 
CRP to each patient. Additionally, since the decision to initiate thoracentesis was based 















6.1 lobar bacterial distributions in patients with bronchiectasis 
In conclusion, this retrospective cohort study allowed us to show the effect of age on the 
bacterial pathogenic profile in bronchiectatic patients with infective exacerbations. We 
found H. influenzae to be more prevalent in younger patients, whereas P. aeruginosa, 
Enterobacteriaceae and NTM were more frequently isolated from older patients. 
Pathogens were also associated with different lobar distributions, with the RML, RLL 
and LLL showing a greater tendency to develop bronchiectasis than other lobes. This 
study highlights the importance of prospective studies in individuals with infectious 
exacerbations of bronchiectasis utilizing age, lobar location and previous bacteriologic 
analyses to inform antibiotic treatment and determine if such treatment can decrease 
morbidity, mortality, recurrent hospitalizations and total cost of care while improving 
quality of life.  
 
6.2 The role of pleural CRP in parapneumonic effusion detection 
Pleural fluid CRP levels can be used to discriminate between parapneumonic effusions 
and other types of exudative effusions, which may help distinguish between exudative 
and transudative effusions. A CRP level >1.38 mg/dl indicates the strong possibility of a 
parapneumonic effusion, whereas a level <0.64 mg/dl indicates a heart failure pleural 
effusion. This study highlights the need for prospective studies to demonstrate the 
prognostic effect of pleural CRP as an effective diagnostic biomarker. If confirmed in 
future studies, our results support the introduction of pleural fluid CRP into clinical 
practice for accurate detection of patients who may benefit from the initiation of antibiotic 















Non-cystic fibrosis bronchiectasis (NCFBr) is a major cause of morbidity and frequent 
hospitalization due to frequent infectious exacerbations. In addition, those infectious 
exacerbations can easily evolve to parapneumonic effusion, which increases the 
morbidity dramatically. We analyzed the influence of patient's age and bronchiectasis 
location on the bacterial profile of patients with NCFBr. We also studied the usefulness 
of pleural C-reactive protein (CRP) biomarker levels in identifying parapneumonic 
effusion, which is potential complication in patients with bronchiectasis.  
This was a single-center, retrospective review of 244 patients diagnosed with pleural 
effusions and 339 subjects with bronchiectasis exacerbation. The study involved patients 
at the Rabin Medical Center, Petach Tikva, Israel, between January 2006 and December 
2014. 
We found that H. influenzae was more prevalent in younger patients who have 
bronchiectasis, whereas P. aeruginosa, Enterobacteriaceae and NTM predominated in 
older patients. Different pathogens were associated with different lobar distributions. 
In the lower lobes, H. influenzae was the dominant species isolated, whereas in the upper 
lobes and lingula it was non-tuberculous mycobacterium (NTM). While Streptococci 
species were more prevalent in LLL and RUL, P. auriginosa was homogenously 
distributed in all the lobes. These findings can support decision making on empirical 
treatment. Overall, the RML, RLL and LLL showed a greater tendency to develop 
bronchiectasis than other lobes.  
On the base of these findings we recommend frequent screening of NTM in older patient 
(age>65) with bilateral disease and upper lobes bronchiectasis.     
Pleural fluid CRP levels can be used to distinguish among parapneumonic effusions and 
other types of exudative effusions. CRP levels < 0.64 mg/dl are likely to indicate a pleural 
effusion from congestive heart failure, whereas levels ≥ 1.38 mg/dl are suggestive of an 
infectious etiology. While we have clear criteria for empyema, we do not have such for 
parapneumonic effusion. In order to facilitate the initial clinical work up, we recommend 
using pleural CRP in addition to the conservative pleural parameters. This is especially 









A nem cisztás fibrózis eredetű bronchiectasia a gyakori fertőzéses exacerbatio miatt a 
megnövekedett morbiditás és a frekvens hoszpitalizació egyik jelentős oka. A fertőzéses 
exacerbatioból könnyedén alakul ki parapneumonia - pneumónia, empyema, 
bronchiectasia - okozta folyadékgyülem, mely drámaian növeli a morbiditás mértékét. 
Nem cisztás fibrózis okozta bronchiectasiaban szenvedő betegeknél vizsgáltuk az életkor, 
a bronchiectasia lokalizáció és bakteriális profil befolyásoló hatását. Mindezek mellett, a 
C-reaktív protein (CRP) biomarker szint hasznosságát tanulmányoztuk a parapneumonia 
okozta pleurális effúzió felismerésében, amely a bronchiectasia potenciális szövődménye.  
Ez egy egy központú, retrospektív tanulmány, melyben 244 pleurális folyadékgyülemmel 
és 339 bronchiectasiával diagnosztizált egyed vizsgálatára került sor 2006. január és 
2014. decembere közt. A tanulmányban résztvevő egyedek a petach tikvai Rabin Medical 
Center, betegei Izraelben. 
Eredményeink szerint a fiatalabb, bronchiectasival küzdő egyének között magasabb a H. 
influenzae prevalenciája, mindemellett idősebb betegeknél a predomináns patogének 
köze a P. aeruginosa, Enterobacteriaceae és a non-tuberculous mycobacterium (NTM) 
sorolható.  Jellemző patogén disztribúció figyelhető meg különböző lobáris 
lokalizációkban.Vizsgálataink alapján az alsó lebenyekből izolált domináns, fertőzést 
okozó baktérium a H. influenzae, mig a felső lebenyekben és a lingulában, e posztot az 
NTM veszi át. Streptococcus spp. prevalenciája a bal alsó valamint a jobb felső lebenyben 
jelentős, míg a P. aeruginosa esetében homogen disztribució figyelhető meg. Ezek az 
eredmények vélhetően stabilabb támaszt nyújtanak az empirikus terápia kiválasztásánál. 
Összegezve, a bronchiectasia kialakulásának magasabb tendenciája figyelhető meg a jobb 
középső, jobb alsó és bal alsó lebenyekben. 
Megállapításaink alapján az NTM gyakori szűrését javasoljuk idősebb (>=65 év), 
bilaterális valamint felső lebeny bronchectasiában szenvedő betegeknél. 
A pleurális folyadékgyülemből nyert CRP szint ideális a parapneumonia okozta pleurális 
effúzó és egyéb etiológiájú exudatív folyamat megkülönböztetésére. 0.64 mg/ml alatti 
CRP érték congestiv szivelégtelenség okozta pleurális folyadékgyülem indikátora lehet, 
míg >=1.38 mg/ml feletti érték fertőzéses eredetre utal. Mindamellett, hogy világos 
diagnosztikai kritériumokkal rendelkezünk empyema esetében, ugyan ez nem mondható 




facilitáljuk a kivizsgálást, a konzervatív pleurális paraméterek mellett javasoljuk a 
pleurális folyadék CRP tartalmának vizsgálatát is. Ez kifejezetten multiplex 
komorbiditásoktól szenvedő betegeknél fontos, ahol a mellkasi folyadékgyülem 
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